BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

July 12, 2022 15:47:04

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point for high fluorescence intensity in the hind paws. The results of this new study show that the time kinetics and quantitative aspects of liposomes administered subcutaneous were not much different from that of liposomes injected i.v. In fact, despite some initial delay, the signal strength showed a trend towards a higher level in subcutaneous than in i.v.”

To view the full press release, visit

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork